Creatine plays a pivotal role in brain bioenergetics, acting as a temporal and spatial energy buffer, energy transducer, and metabolic regulator. A low cerebral creatine concentration illustrating energy depletion has been routinely observed in various neuropathologies, including cerebrovascular diseases, brain neoplasms, inborn disorders of creatine metabolism, and age-related conditions. (
Niedzwiecki et al., 2020) White matter disorders (WMD), however, appear to encounter a different dynamics in brain creatine variation that could be potentially useful in the disease screening and prognosis.
- Niedzwiecki MM
- Walker DI
- Howell JC
- et al.
High-resolution metabolomic profiling of Alzheimer's disease in plasma.
Ann. Clin. Transl. Neurol. 2020; 7: 36-45
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- High-resolution metabolomic profiling of Alzheimer's disease in plasma.Ann. Clin. Transl. Neurol. 2020; 7: 36-45
- Proton MR spectroscopy of lesion evolution in multiple sclerosis: Steady-state metabolism and its relationship to conventional imaging.Hum. Brain Mapp. 2017; 38: 4047-4063
- Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.Mult. Scler. 2018; 24: 491-500
- Quantitative MR spectroscopic imaging in metachromatic leukodystrophy: value for prognosis and treatment.J. Neurol. Neurosurg. Psychiatry. 2018; 89: 105-111
- Creatine as a booster for human brain function. How might it work?.Neurochem. Int. 2015; 89: 249-259
- Longitudinal absolute metabolite quantification of white and gray matter regions in healthy controls using proton MR spectroscopic imaging.NMR Biomed. 2014; 27: 304-311
- Proton NMR chemical shifts and coupling constants for brain metabolites.NMR Biomed. 2000; 13: 129-153
- Combined (1)H and (31)P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis.NMR Biomed. 2011; 24: 536-546
- Adenosine triphosphate metabolism measured by phosphorus magnetic resonance spectroscopy: a potential biomarker for multiple sclerosis severity.Eur. Neurol. 2017; 77: 316-321
- Targeting phosphocreatine metabolism in relapsing–remitting multiple sclerosis: evaluation with brain MRI, 1 H and 31 P MRS, and clinical and cognitive testing.J. Neurol. 2018; 265: 2614-2624
- When are metabolic ratios superior to absolute quantification? A statistical analysis.NMR Biomed. 2017; 30: e3710
- Progressive multiple sclerosis: latest therapeutic developments and future directions.Ther. Adv. Neurol. Disord. 2019; 121756286419878323
Published online: August 04, 2020
Accepted: August 3, 2020
Received in revised form: July 29, 2020
Received: May 29, 2020
© 2020 Elsevier B.V. All rights reserved.